TY - JOUR
T1 - Effect of montelukast and fluticasone propionate on airway mucosal blood flow in asthma
AU - Mendes, Eliana S.
AU - Campos, Michael A.
AU - Hurtado, Andres
AU - Wanner, Adam
PY - 2004/5/15
Y1 - 2004/5/15
N2 - Asthma is associated with an increase in airway blood flow (Q̇aw), presumably as a manifestation of airway inflammation. We therefore determined the effect of the antiinflammatory agents montelukast (ML) and fluticasone propionate (FP) on Q̇aw in 12 patients with mild intermittent asthma. Using a double-blind approach, Q̇aw along with FEV1 and V̇max 50 were determined before and after a 2-week treatment period with either ML (10 mg/day), FP (440 μg/day), or 10 mg of ML plus 440 μg of FP daily, separated by 2-week washout periods. Mean (± SEM) Q̇aw ranged from 68 ± 4.2 to 71.8 ± 5.9 μl·minute -1·ml-1 anatomic dead space before the treatment periods. ML, FP, and ML plus FP decreased mean Q̇aw by 21.5, 20.8, and 26.9%, respectively (p < 0.05 for all). No significant difference was observed among the three regimens. FEV1 and V̇max50 were not changed by any of the treatments. We conclude that at the dosages used, ML and FP are equipotent in reducing Q̇aw in patients with mild asthma, and that the magnitude of the response is not greater if the two drugs are combined. The results also suggest that the vascular effects of these agents can be assessed independent of their effects on airway function.
AB - Asthma is associated with an increase in airway blood flow (Q̇aw), presumably as a manifestation of airway inflammation. We therefore determined the effect of the antiinflammatory agents montelukast (ML) and fluticasone propionate (FP) on Q̇aw in 12 patients with mild intermittent asthma. Using a double-blind approach, Q̇aw along with FEV1 and V̇max 50 were determined before and after a 2-week treatment period with either ML (10 mg/day), FP (440 μg/day), or 10 mg of ML plus 440 μg of FP daily, separated by 2-week washout periods. Mean (± SEM) Q̇aw ranged from 68 ± 4.2 to 71.8 ± 5.9 μl·minute -1·ml-1 anatomic dead space before the treatment periods. ML, FP, and ML plus FP decreased mean Q̇aw by 21.5, 20.8, and 26.9%, respectively (p < 0.05 for all). No significant difference was observed among the three regimens. FEV1 and V̇max50 were not changed by any of the treatments. We conclude that at the dosages used, ML and FP are equipotent in reducing Q̇aw in patients with mild asthma, and that the magnitude of the response is not greater if the two drugs are combined. The results also suggest that the vascular effects of these agents can be assessed independent of their effects on airway function.
KW - Airway inflammation
KW - Asthma
KW - Bronchial circulation
KW - Glucocorticosteroids
KW - Leukotriene modifiers
UR - http://www.scopus.com/inward/record.url?scp=2442528995&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2442528995&partnerID=8YFLogxK
U2 - 10.1164/rccm.200311-1544oc
DO - 10.1164/rccm.200311-1544oc
M3 - Article
C2 - 15028562
AN - SCOPUS:2442528995
VL - 169
SP - 1131
EP - 1134
JO - American Journal of Respiratory and Critical Care Medicine
JF - American Journal of Respiratory and Critical Care Medicine
SN - 1073-449X
IS - 10
ER -